We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?
Read MoreHide Full Article
Obalon Therapeutics, Inc. is scheduled to report third-quarter 2018 results on Nov 2, after the market closes.
Last reported quarter, the company’s earnings per share topped the Zacks Consensus Estimate by 214%. It delivered positive surprises in two of the trailing four quarters with the average beat being 32.4%.
Let’s see, how things are shaping up prior to this announcement.
Factors at Play
In the third quarter, Obalon is expected to register strong U.S. revenues on the back of increased reorders from existing accounts and new order bookings. Per Obalon, it is meaningfully working on value creation within the United States and plans to continue making this geographical region its highest priority for 2018 and beyond.
Meanwhile, International sales are expected to see a strong revenue contribution from its current-generation six-month duration Obalon Balloon product to the company’s Middle East distributor. Notably, in the second quarter, the company registered international sales of $1.2 million as compared to about $800,000 during the first quarter. This uptrend is expected to get reflected in the third quarter numbers as well.
Earlier this year, the company expanded its long-term relationship with Sono Bello within retail medicine. According to Obalon, Sono Bello has further extended the number of accounts treating, thereby improving the company’s retail medicine capabilities. We expect this to further positively impact the company’s yet-to-be-reported quarter’s figures.
In the last few quarters, Obalon faced clinical logistics issues (time and cost associated with the account initiation) related to the acquisition of new account. However, in the second quarter, the company developed new value-added partnership programs to reduce the burden of clinical logistics for a potential new account. This includes plans to help the company acquire x-ray imaging until Obalon Navigation becomes available in the United States. The same should also leave a favorable effect on the company’s third-quarter new order result.
Here’s What Our Quantitative Model Predicts
Our proven Zacks model indicates that a company with a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has maximum chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Obalon has a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s Earnings ESP of 0.00% makes surprise prediction difficult. Thus, this combination fails to forecast an earnings beat.
Stocks Worth a Look
Here are a few medical stocks worth considering with the right combination of elements to beat on earnings in the upcoming quarterly results.
Humana Inc. (HUM - Free Report) has an Earnings ESP of +2.22% and a Zacks Rank #2.
Natera, Inc. (NTRA - Free Report) has an Earnings ESP of +6.01% and a Zacks Rank of 2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?
Obalon Therapeutics, Inc. is scheduled to report third-quarter 2018 results on Nov 2, after the market closes.
Last reported quarter, the company’s earnings per share topped the Zacks Consensus Estimate by 214%. It delivered positive surprises in two of the trailing four quarters with the average beat being 32.4%.
Let’s see, how things are shaping up prior to this announcement.
Factors at Play
In the third quarter, Obalon is expected to register strong U.S. revenues on the back of increased reorders from existing accounts and new order bookings. Per Obalon, it is meaningfully working on value creation within the United States and plans to continue making this geographical region its highest priority for 2018 and beyond.
Meanwhile, International sales are expected to see a strong revenue contribution from its current-generation six-month duration Obalon Balloon product to the company’s Middle East distributor. Notably, in the second quarter, the company registered international sales of $1.2 million as compared to about $800,000 during the first quarter. This uptrend is expected to get reflected in the third quarter numbers as well.
Earlier this year, the company expanded its long-term relationship with Sono Bello within retail medicine. According to Obalon, Sono Bello has further extended the number of accounts treating, thereby improving the company’s retail medicine capabilities. We expect this to further positively impact the company’s yet-to-be-reported quarter’s figures.
OBALON THERPTCS Price and EPS Surprise
OBALON THERPTCS Price and EPS Surprise | OBALON THERPTCS Quote
In the last few quarters, Obalon faced clinical logistics issues (time and cost associated with the account initiation) related to the acquisition of new account. However, in the second quarter, the company developed new value-added partnership programs to reduce the burden of clinical logistics for a potential new account. This includes plans to help the company acquire x-ray imaging until Obalon Navigation becomes available in the United States. The same should also leave a favorable effect on the company’s third-quarter new order result.
Here’s What Our Quantitative Model Predicts
Our proven Zacks model indicates that a company with a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has maximum chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Obalon has a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s Earnings ESP of 0.00% makes surprise prediction difficult. Thus, this combination fails to forecast an earnings beat.
Stocks Worth a Look
Here are a few medical stocks worth considering with the right combination of elements to beat on earnings in the upcoming quarterly results.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Humana Inc. (HUM - Free Report) has an Earnings ESP of +2.22% and a Zacks Rank #2.
Natera, Inc. (NTRA - Free Report) has an Earnings ESP of +6.01% and a Zacks Rank of 2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>